Envafolimab
- Generic Name
- Envafolimab
- Drug Type
- Biotech
- CAS Number
- 2102192-68-5
- Unique Ingredient Identifier
- ES1M06M6QH
- Indication
用于不可切除或转移性微卫星高度不稳定（MSI-H）或错配修复基因缺陷型（dMMR）的成人晚期实体瘤患者的治疗，包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Rectal Cancer
- Interventions
- Radiation: split-course hypofraction radiotherapyDrug: CAPOXProcedure: Local excision
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- 池畔
- Target Recruit Count
- 72
- Registration Number
- NCT05969847
- Locations
- 🇨🇳
Pan Chi, Fuzhou, Fujian, China
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Phase 2
Recruiting
- Conditions
- Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shanghai 6th People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05941325
- Locations
- 🇨🇳
Shanghai No.6 People Hospital, Shanghai, Shanghai, China
The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Phase 2
Not yet recruiting
- Conditions
- Lung Neoplasms
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Target Recruit Count
- 80
- Registration Number
- NCT05904015
Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer
Not yet recruiting
- Conditions
- Cervical Cancer
- Interventions
- Drug: cis-platinumRadiation: radiation
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05879796
Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05858567
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Phase I Trial of Envafolimab for Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT05849311
- Locations
- 🇨🇳
Beijing Gaobo Boren Hosipital, Beijing, Beijing, China
Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer
Phase 2
Not yet recruiting
- Conditions
- Immunotherapy;Envafolimab; Esophageal Cancer
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT05828381
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Radiation: External Beam Radiotherapy (EBRT)Radiation: Brachytherapy (BT)
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT05799469
- Locations
- 🇨🇳
Chongqing university Cancer Hospital, Chongqing, CHN, China
Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer
Not yet recruiting
- Conditions
- Locally Advanced Rectal CarcinomaMSI-High
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 38
- Registration Number
- NCT05645094
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Tao Jiang
- Target Recruit Count
- 40
- Registration Number
- NCT05552651
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath